Skip to content

Anavatos Bio

Automated small-batch protein manufacturing

Raised to date

$393K

across 1 Form D filing

Investors
4
Last filed
Jul 20, 2026

About

Anavatos Bio is an early-stage Seattle biotechnology company building next-generation protein manufacturing technology for small-batch biologics. Its fit-for-purpose, plug-and-play automated protein manufacturing platform is aimed at early-phase research, pre-clinical, and Phase I clinical material. The company says the platform produces formulated protein from industry-standard materials in eight weeks at 10x less cost than conventional approaches. It was founded in 2025 and is led by Founder and CEO Leah Klein.

Point-of-need, automated small-batch protein manufacturing that skips centralized CDMO scale, quoted at eight-week turnaround and 10x lower cost using industry-standard materials.

Funding

  • DebtFiled Jul 20, 2026Form D/A
    $393K/ no target

Product

Automated Protein Manufacturing Platform

Biologics manufacturing platform

An integrated small-batch manufacturing platform that automates production of custom-designed proteins at the point of need, delivering formulated protein rather than a research-grade prep.

  • Fit-for-purpose, plug-and-play automated protein production
  • Small-batch scale suited to research, pre-clinical, and Phase I material
  • Uses industry-standard materials

Built for

Biotech and academic research groups needing designer proteins for early-phase research, pre-clinical work, and Phase I clinical products

People on file